Home > Dermatology > Cantharidin-based drug-device combination likely safe, effective for molluscum contagiosum

Cantharidin-based drug-device combination likely safe, effective for molluscum contagiosum

Journal
JAMA Dermatology
Reuters Health - 03/10/2020 - VP-102, a proprietary drug-device combination containing 0.7% cantharidin, was safe and effective in two phase 3 trials in children with molluscum contagiosum (MC). Dr. Gary Goldenberg, Chief Medical Officer of study sponsor Verrica Pharmaceuticals in West Chester, Pennsylvania, told Reuters Health by email, "Molluscum contagiosum is one of the most common viral skin infections in children and one of the five most prevalent skin diseases worldwide. Yet, there are no FDA-approved treatments for (it)." "The positive results from Verrica's Phase 3 CAMP (Cantharidin Application in Molluscum Patients) trials demonstrate that VP-102, which is delivered via a single-use applicator that allows for precise topical dosing and targeted administration, may be a viable treatment option for pediatric and adult patients with molluscum," he said. "Verrica's next expected milestone for VP-102 is a Type A Meeting with the FDA during September/Octo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on